AeRang Kim

Director, Clinical Research, Oncology Program · George Washington University School of Medicine

Credentials: · · · ·

History

Clinical Research · George Washington University School of Medicine
Present
George Washington University School of Medicine
Present
George Washington University School of Medicine
Present

Hematology and Medical Oncology
2004–2007
Internal Medicine
2001–2004
University of Illinois College of Medicine
1997–2001

Research

Selumetinib in Children with Inoperable Plexiform Neurofibromas
New England Journal of Medicine · 2020 · 550 citations
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
New England Journal of Medicine · 2016 · 531 citations
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a…
Review · Human Pathology · 2017 · 315 citations

Brigitte Widemann
37 papers
Andrea Gross
12 papers
Katherine Janeway
11 papers
Michael Fisher
11 papers
Frank Balis
10 papers
Brian Weiss
9 papers
JB
Julia Bender
9 papers
Karun Sharma
9 papers
Miriam Bornhorst
7 papers
Steven DuBois
7 papers
Alanna Church
6 papers
Brenda Weigel
6 papers

Grants

Bench to Bedside: Non-Invasive Treatment of Tumors in Children
National Cancer Institute · U01
PI · $245.1K · Children's Research Institute
2017–2024
Early Phase Clinical Trials in Imaging and Image-Guided Interventions
National Cancer Institute · R01
Contact PI · $773K · Children's Research Institute
2015–2020

Clinical trials

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Principal investigator · Active not recruiting · Phase 1
Valent Technologies, LLC
2021–2026
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Principal investigator · Completed · Phase 2
Sarcoma Alliance for Research through Collaboration
2019–2023
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2017–2024
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Principal investigator · Completed · Phase 1, Phase 2
Sarcoma Alliance for Research through Collaboration
2013–2018